Postmenopausal Osteoporosis Market Segmentation:
Type Segment Analysis
The pharmacological therapies segment in the postmenopausal osteoporosis market is estimated to gain the largest revenue share of about 60% in the year 2035. The segment growth can be set to the evolving treatment paradigms and improved safety profiles. A landmark clinical trial demonstrated that raloxifene, a widely used SERM, significantly reduced the risk of vertebral fractures by 30-50% in postmenopausal women. The study also highlighted the positive impact of SERMs on bone mineral density.
As treatment paradigms evolve towards personalized medicine, the safety profiles of SERMs make them a favorable choice for women with specific health considerations, such as a history of breast cancer. The balance of efficacy and safety positions SERMs as a key growth driver in the pharmacological armamentarium against postmenopausal osteoporosis. Monoclonal antibodies, particularly denosumab, have gained momentum in the postmenopausal osteoporosis market propelled by their enhanced efficacy and targeted action mechanisms.
End User Segment Analysis
Based on end user, hospitals segment is expected to hold largest revenue share of about 45% by 2035. For the hospital segment, the rising number of fractures linked to osteoporosis is a major growth driver for postmenopausal osteoporosis market in this segment. A large proportion of fractures, especially hip fractures in the senior population, are caused by osteoporosis, according to a study published in the Journal of the American Geriatrics Society. The study reported that over 300,000 hip fractures occur annually in the United States, leading to hospitalizations.
As fractures often necessitate immediate medical attention and specialized care, hospitals experience a surge in demand for their services. The rising number of osteoporosis-related fractures reinforces the importance of hospitals as key providers of comprehensive care, driving growth in this segment. The growth of hospitals in the market expansion is influenced by the increasing number of surgical interventions for osteoporotic fractures.
Our in-depth analysis of the global postmenopausal osteoporosis market includes the following segments:
|
Type |
|
|
End User |
|
|
Risk Factors |
|
|
Comorbid Conditions |
|
